TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01561989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trivalent influenza vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trivalent influenza vaccine
Description: Given IM
Study: NCT04304924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The personalized telephone based intervention
Description: The personalized telephone based intervention:~1. Provide Behavioral support to facilitate lifestyle change by a weight loss coach located at a centralized call center. Participants will be paired with an individual coach who will work with the participant through all phases of the 1-year weight loss program. The behavior change program will be based on Social Cognitive Theory, which hypothesizes that the interactions between environmental, personal and behavioral elements determine behavioral change (Bandura 1989);~2. Utilize a toolbox approach that will allow for tailoring the intervention to the individual participant. Examples of possible Toolbox solutions include: alternative dietary approaches, instructions for strength-training exercises.
Study: NCT03126357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: FT21092 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C
Description: FT21092 an electronic tobacco vapor product
Study: NCT00503542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole or Clindamycin for Bacterial Vaginosis
Description: Metronidazole 500 mg bid x 5 days; Intravaginal metronidazole bid x 5 days; intravaginal clindamycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole or Clindamycin for Bacterial Vaginosis
Description: Metronidazole 500 mg bid x 5 days; Intravaginal metronidazole bid x 5 days; intravaginal clindamycin
Study: NCT02161536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motus Cleansing System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motus Cleansing System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motus Cleansing System
Study: NCT03758183

Intervention type: PROCEDURE
Intervention: total knee arthroplasty

Intervention type: PROCEDURE
Intervention: total knee arthroplasty
Study: NCT01679483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FloSeal application
Description: At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
Study: NCT03554655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Momentum app
Description: The Momentum system consists of a smartphone app (for the patient) and a web portal (for the provider). Information entered in the app by the patient will automatically be transferred to the web portal for the provider to see. While one goal of the system is to support SDM, the Momentum app is not a classic decision aid focusing on finding a choice to a one-off treatment decision. Instead, the Momentum app is an aid to support some of the underlying elements behind SDM such as collaboration with one's provider, awareness and eliciting of one's needs, preferences and values.
Study: NCT00190671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 600 mg/m2, intravenous (IV), every 21 days x 8 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 1800 mg/m2, intravenous (IV), every 21 days x 8 cycles
Study: NCT01620684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metyrapone
Description: Overnight treatment (15 mg/kg at midnight and 15 mg/kg at 6 am)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsules
Study: NCT02240446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: 2mA stimulation for 20 minutes twice a day for five consecutive days

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: 2mA for 30 seconds twice a day for five consecutive days
Study: NCT02633267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vocational Services as usual plus Cognitive Behavioral Therapy (CBT)
Description: Teaches thought restructuring and exposure therapy to socially anxious job seekers delivered by vocational service professionals

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Vocational Services
Description: Vocational services delivered by vocational professionals at vocational service center (e.g., resume assistance, job leads)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Vocational Services
Description: Vocational services delivered by vocational professionals at vocational service center (e.g., resume assistance, job leads)
Study: NCT02990949

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Timing of trigger
Study: NCT00697489

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: correction of POP plus preventive continence procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: POP surgery followed by eventual incontinence procedure
Study: NCT03981926

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Team-Based Connected Health (TCH)
Description: TCH is an asynchronous, secure online platform where patients can upload images of atopic dermatitis disease and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
Study: NCT01598259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: po 1 hour before bedtime
Study: NCT01546805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Supplement
Description: The interventional group will be requested to take zinc supplements (50mg), once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: The control group will be requested to take placebo pills, once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
Study: NCT02066142

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3D mammography (Tomosynthesis)
Description: Tomosynthesis will be used as normally employed in clinical practice

Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound
Study: NCT01646762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01478477

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid supplement
Description: 6 capsules per day (4.3 g)x 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid supplement
Description: 6 capsules per day (4.3 g)x 6 months
Study: NCT01598259

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: po, 1 hour before bed
Study: NCT01824485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: viscosupplementation 1+1+1
Description: intra-articular injection with 1 ampoule per week for 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: viscosupplementation 3 at once
Description: single intra-articular injection with 3 ampoules
Study: NCT00503542

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flagyl for definitively diagnosed vaginal trichomoniasis
Description: Metronidazole 2 gms po x 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flagyl for definitively diagnosed vaginal trichomoniasis
Description: Metronidazole 2 gms po x 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Empiric Management
Description: In this arm of the study women are treated for vaginal complaints purely on the basis of their symptoms.
Study: NCT04507620

Intervention type: DEVICE
Intervention: cervical neck collar
Description: devices used for cervical immobilization

Intervention type: DEVICE
Intervention: cervical neck collar
Description: devices used for cervical immobilization
Study: NCT02193815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF06263276
Description: 4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Active ingredient-free vehicle to 4% solution
Study: NCT00943358

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MF59 H1N1 vaccine
Description: 3.75-7.5ug dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plain H1N1 vaccine
Description: 7.5-15ug
Study: NCT01478477

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid supplement
Description: 6 capsules per day (4.3 g)x 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid supplement
Description: 6 capsules per day (4.3 g)x 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid supplement
Description: 6 capsules per day (4.3 g)x 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 capsules per day (4.3 g)x 6 months. Supplement should be taken with food once per day. No specific food requirements are needed.
Study: NCT04999735

Intervention type: BEHAVIORAL
Intervention: Withings Body+ scale
Description: Body composition (weight, BMI and Skeletal Muscle Mass) can be assessed with the Withings Body+ smart scale at home. A smart phone is required to store data and send collected data to the output server. The device does not require charging.

Intervention type: BEHAVIORAL
Intervention: Withings Blood Pressure Monitor
Description: Blood pressure can be assessed with the automated Withings Blood Pressure Monitor at home. A smart phone is required to store data and send collected data to the output server. The device does not require charging
Study: NCT03606512

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.RSV.preF
Description: Ad26.RSV.preF will be administered as IM injection at a dose of 2.5\*10\^10 vp.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as IM injection of sterile 0.9 percent (%) saline for injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Nimenrix
Description: Nimenrix will be administered as 0.5 milliliter (mL) solution for IM injection.
Study: NCT04905758

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: platform switching
Description: reduced implant abutment interface

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: platform amtching
Description: matched implant abutment interface
Study: NCT04999735

Intervention type: BEHAVIORAL
Intervention: Withings Blood Pressure Monitor
Description: Blood pressure can be assessed with the automated Withings Blood Pressure Monitor at home. A smart phone is required to store data and send collected data to the output server. The device does not require charging
Study: NCT00529672

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: crossectomy and short stripping
Description: under spinal or complete anaesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided sclerotherapy with foam
Description: 1 part 3% polidocanol mixed with 3 parts of air. Between 3cc - 12 cc per varicose vein\>
Study: NCT00529672

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endovenous laser therapy
Description: 940 nm Diode laser. About 70 J/cm will be administered. Disposables from Angiocare (registered) will be used.
Study: NCT03005340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment B
Description: Bazedoxifene 20 mg
Study: NCT02193815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2%Tofacitinib Ointment
Description: Daily Dosage: approximately 4 mg tofacitinib

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vehicle
Description: Active ingredient-free vehicle to 2% Ointment
Study: NCT03126357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: FT21018 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: FT21018 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: FT21018 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: FT21018 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: FT21018 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: FT21018 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: FT21018 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: FT21018 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: FT21018 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D
Description: FT21018 an electronic tobacco vapor product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: 4mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: 4mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: 4mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: 4mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: 4mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: 4mg nicotine gum
Study: NCT02193815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivonex
Description: Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daivonex Ointment
Description: Daivonex ointment (50 ug/g Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
Study: NCT03126357

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: 4mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: 4mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: 4mg nicotine gum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E
Description: 4mg nicotine gum
Study: NCT01301508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 ointment, 2%
Description: AN2728 ointment, 2%, applied twice daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2898 ointment, 1%
Description: AN2898 ointment, 1%, applied twice daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2898 ointment vehicle
Description: AN2898 ointment vehicle applied twice daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN2728 ointment vehicle
Description: AN2728 ointment vehicle applied twice daily for 6 weeks
Study: NCT03436914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI
Description: After the diagnosis of NERD through patient's symptom and endoscopy, PPI (esomezol) will be given for 8 weeks. The effect of PPI for NERD patients will be analyzed.
Study: NCT00934427

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% nitroglycerin in TAM cream
Description: 0.5 g of Vascana (0.9% nitroglycerin in proprietary vehicle cream) is applied topically BID for one day before certain planned cold exposures, once just before same planned cold exposures, and, if needed, right after the start of symptoms during same planned cold exposures

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle cream
Description: 0.5g of vehicle cream is topically administered BID for one day before certain planned cold exposures, once just before certain planned cold exposures, and, if needed, right after the start of symptoms during certain planned cold exposures
Study: NCT02425007

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incentive spirometry
Study: NCT00939224

Intervention type: DEVICE
Intervention: Model 7600 Regional Oximeter System
Description: Non-invasive regional oxygen saturation measurements
Study: NCT01721031

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DPNB
Description: Patients receive DPNB 30min before extubation at the end of operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Patients receive intravenous tramadol 1.5mg/kg 30min before extubation at the end of operation.
Study: NCT04204759

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Non-invasive stimulation will be conducted using a tDCS device (StarStim, Neuroelectrics, Spain).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham transcranial direct current stimulation
Description: The same device will be used as in the active stimulation group, but stimulation will be terminated after 30 seconds.
Study: NCT02476357

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Harmonic scalpel
Study: NCT03005340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment B
Description: Bazedoxifene 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment B
Description: Bazedoxifene 20 mg
Study: NCT04619264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Papacarie
Description: First, tooth was cleaned with a wet cotton pellet. The gel was inserted using disposable syringe tip into the cavity and its color changed from clear to cloudy indicating the presence of infected tissues. After 40 seconds, the softened carious tissue was removed using excavator by gentle pressure. The remaining gel was removed with a cotton pellet. The procedure was repeated until there was no change in the gel color indicating that there was no more infected tissue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Atraumatic Restorative Treatment
Description: The tooth was cleaned with a wet cotton pellet to remove debris and plaque and then isolated with cotton rolls to promote a dry environment. Caries was removed using a sharp excavator and the cavity was cleaned using a small wet cotton pellet and dried with a dry cotton pellet.
Study: NCT03225716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulocuplumab
Description: Ulocuplumab is a type of protein called an antibody that attacks CXCR4
Study: NCT03225716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulocuplumab
Description: Ulocuplumab is a type of protein called an antibody that attacks CXCR4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulocuplumab
Description: Ulocuplumab is a type of protein called an antibody that attacks CXCR4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity
Study: NCT03005340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment B
Description: Bazedoxifene 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment C
Description: Cholecalciferol granule 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment C
Description: Cholecalciferol granule 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment C
Description: Cholecalciferol granule 10 mg
Study: NCT03225716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity
Study: NCT02559154

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxsnteone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxsnteone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Study: NCT03005340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment C
Description: Cholecalciferol granule 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment C
Description: Cholecalciferol granule 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment C
Description: Cholecalciferol granule 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment BC
Description: Bazedoxifene 20 mg, Cholecalciferol granule 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment BC
Description: Bazedoxifene 20 mg, Cholecalciferol granule 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment BC
Description: Bazedoxifene 20 mg, Cholecalciferol granule 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment BC
Description: Bazedoxifene 20 mg, Cholecalciferol granule 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment BC
Description: Bazedoxifene 20 mg, Cholecalciferol granule 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment BC
Description: Bazedoxifene 20 mg, Cholecalciferol granule 10 mg
Study: NCT04382443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: At the moment of BMS implantation intervention will mean that this group will receive colchicine as described.
Study: NCT01474967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks